This report was first published by Endpoints News. To see the original version, click here
Pharmaceutical companies are on a dealmaking tear.
Six pharma companies have signed acquisitions worth up to $25.5 billion since the beginning of last week. Two $5 billion-plus upfront deals were disclosed on Tuesday morning alone: Eli Lilly’s bet on Centessa Pharmaceuticals’ orexins and Biogen’s consummation of commercial player Apellis Pharmaceuticals. There were a total of seven deals of that magnitude in all of 2025.
您已阅读14%（513字），剩余86%（3270字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。